Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Newly NASDAQ-listed China Nuokang Sees Revenue Growth Spurt

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Underscoring the potential for growth for small biopharmaceutical companies, a Chinese developer and manufacturer of hematological and cardiovascular products reported higher earnings for 2009 and expects growth to carry into 2010

You may also be interested in...

Financings Of The Fortnight: Top-Ups The Latest Trend In Biopharmaceutical Deals

China Nuokang Bio-Pharmaceutical, Dendreon, Afferent Pharmaceuticals, and Molecular Partners end the year with new funds.

The Year Of The Tiger Looking Strong For IPOs In China Following Sinopharm Success

HONG KONG - Concerns over valuation seem to be doing little to dampen enthusiasm for new Chinese pharmaceutical related stocks and the result is a minefield of opportunities on very shaky ground

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts